Hepatocytes Differentiation Service from iPSC

Reference the resources below for more information about the product/service or contact us today to learn more.
Catalog # :
Format :
  • Description
  • Related Products

Hepatocyte Differentiation Service

iPSC-derived hepatocytes are liver cells that are generated from induced pluripotent stem cells (iPSCs), which are reprogrammed adult cells that have the ability to differentiate into many different cell types, including liver cells. Hepatocytes are the main functional cells of the liver, responsible for a wide range of metabolic and detoxification processes.

iPSC-derived hepatocytes can be generated through a process of differentiation that mimics the natural development of liver cells in the developing embryo. This involves the sequential activation of different genes and signaling pathways that direct the iPSCs towards a hepatocyte fate.

The ability to generate iPSC-derived hepatocytes has several important applications in research and medicine. For example, iPSC-derived hepatocytes can be used as a model for studying liver diseases and drug toxicity. By generating hepatocytes from iPSCs derived from patients with liver diseases, researchers can study the disease mechanisms and test potential therapies in a dish.

Additionally, iPSC-derived hepatocytes have the potential to be used in regenerative medicine. For patients with liver damage or liver failure, transplantation of healthy hepatocytes can be a potential treatment option. However, donor livers are scarce, and transplantation can be associated with complications such as rejection and infection. iPSC-derived hepatocytes could offer a potential alternative, providing a source of functional liver cells that can be generated in large quantities and tailored to individual patient needs.

Standard Packaging:

  • Ship 1-2 million iPS cells (1-2 cryovials; 1 million cells/vial); OR
    • With pathogen and SARS-CoV-2 test results
      • Optional Pathogen Testing Service is available
  • Select one of our Control iPS Cell Lines; OR
  • Let ASC generate your iPSCs from your human or non-human samples

Standard Deliverables:

  • 2 million differentiated cells 
  • Data & Report
    • Biomarkers: AFP, SerpinA1, HNF4a

Standard Workflow and Timeline:

Service Time
Expansion of Host iPSCs  1-2 weeks
Progenitor Cell Differentiation  2-4 weeks
Characterization of Progenitor Cells  2-4 weeks
Terminal Differentiation (4X10^6 cells) 4-10 weeks
Characterization of Progenitor Cells/ Differentiated Cells by ICC (per marker) 2-4 days
Total ~ 1 month


hematopoiesis, cancer immunotherapy, autoimmune diseases/ transplant graft rejection, and drug screening.